A5050047542- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Inflammatory Bowel Disease
- Pharmaceutical studies and practices
- Celiac Disease Research and Management
- Eosinophilic Esophagitis
Immundiagnostik (Germany)
2017
Background: Vedolizumab (VDZ) drug monitoring strategies in inflammatory bowel disease (IBD) patients have not been systematically investigated so far. We evaluated the correlation between VDZ trough levels (VTL) and treatment response IBD.Methods: Fifty-one with active IBD on or starting a therapy were enrolled this prospective observational single centre study. Disease activity indices, blood tests, anthropometric parameters assessed over time period of 6 months. One hundred fifty-five...
Background: Vedolizumab drug monitoring strategies in IBD patients have not been investigated systematically so far. Our aim was to evaluate the correlation between vedolizumab trough levels (VTL) and treatment response with IBD. Methods: 51 adult therapy-refractory chronic active ulcerative colitis (UC) (n=23), Crohn's disease (CD) (n=27) or indeterminate (IC) (n=1) on starting a therapy were enrolled this prospective single center study. Disease activity indices (Harvey-Bradshaw-Index,...
Vedolizumab drug monitoring strategies in IBD patients have not been investigated systematically so far. Our aim was to evaluate the correlation between vedolizumab trough levels (VTL) and treatment response patients.